Keith Kerr graduated BSc with first class honours in Pathology in 1978, MB ChB in 1981, followed by post-graduate training in Pathology at Edinburgh University Medical School and the Royal Infirmary of Edinburgh. He obtained MRCPath in 1988, FRCPath in 1998 and was elected Honorary FRCP(Ed) in 2006. He has been a Consultant Pathologist in Aberdeen since 1989. He was awarded an Honorary Chair in Pulmonary Pathology by the University of Aberdeen in 2006.
He has had a career long interest in lung cancer for over 35 years and has research interests in pulmonary pre-neoplasia and carcinogenesis, in lung tumour diagnosis and classification and in the identification of predictors of therapy response.
He has been a member of IASLC for 16 years and contributed to the last 7 WCLC meetings, including as invited faculty. He is a member of the IASLC Pathology Panel, participated in the 2004 IASLC/ASCO BAC workshop and worked in the core group for the 2011 IASLC/ATS/ERS Adenocarcinoma classification. He is an Associate Editor for the Journal of Thoracic Oncology.
He served on the panel for the 2004 WHO lung cancer classification and is actively contributing to the current revision of this classification. He is a member of the International Mesothelioma Panel, and is Pathology chair for the EORTC lung cancer group and the ETOP Lungscape group. He has worked on numerous clinical research lung cancer trials groups (SLCF, NCRI, UKLS), guideline development for lung cancer diagnosis and management (RCPath, SIGN, NICE, BTS, ESMO, IASLC/ETOP, IASLC/CAP/AMP), conference scientific committees (ELCC, ESMO, BTOG) and other lung cancer organization committees (UKLCC, BTOG). He serves on the international Pulmonary Pathology Society council and is a British Thoracic Society member of more than 30 years.
Throughout his career, he has worked in diagnostic histopathology with a special interest in Thoracic Pathology, but has always maintained close links with the clinical practice of thoracic medicine, especially thoracic oncology. He has maintained an active research interest in his own laboratory as well as through national and international collaboration. He enjoys his ongoing commitments to under- and postgraduate teaching.
He will serve on the IASLC Board of Directors for four years, starting at the WCLC in 2013.
Become a Member
Join the only international association solely dedicated to lung cancer research and treatment.